Tissue Acquisition, Pathology and Clinical Data

组织采集、病理学和临床数据

• 批准号: 7742548
• 负责人: Othon Iliopoulos
• 金额: $ 52.87万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7742548
• 关键词: Arts; Biological Assay; Biopsy; Biostatistics Core; Blood; Blood specimen; Boston; Cancer Center; Cancer Patient; Clear Cell; Clinical; Clinical Data; Collection; Computer-Assisted Image Analysis; Confidentiality of Patient Information; Consent; DNA; Dana-Farber Cancer Institute; Data; Data Analyses; Data Collection; Databases; Equipment and supply inventories; Evaluation; Fluorescent in Situ Hybridization; Freezing; General Hospitals; Generations; Goals; Histology; Hospitals; Immunohistochemistry; In Situ Hybridization; Individual; Informatics; Institution; Israel; Kidney; Kidney Neoplasms; Laboratories; Link; Maintenance; Massachusetts; Medical center; Methylation; Microdissection; Molecular; Mutation; Nephrectomy; Outcome; Pathology; Patients; Pediatric Hospitals; Preparation; Procedures; Process; Protocols documentation; Quality Control; RNA; Renal Cell Carcinoma; Renal carcinoma; Reproduction spores; Research Personnel; Research Project Grants; Resources; Sampling; Secure; Services; Specimen; System; Tissue Banking; Tissue Banks; Tissue Microarray; Tissues; Tumor Tissue; Urine; VHL gene; Woman; data management; molecular pathology; repository; sample collection; tissue fixing

The Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core has several purposes, the first and foremost of which is to maintain a tissue, blood, and urine repository for the various investigators participating in this SPORE. This task involves the collection, freezing and storage of kidney cancer and paired normal kidney tissues as well as blood and urine from consenting RCC patients. As of July 2008, frozen tissue is available on 643 patients. In addition, 1088 patients have at least one blood sample and 741 patients have at least one urine sample stored in the specimen repository. The TAPCD Core is also responsible for the maintenance of a clinical database on all consenting kidney cancer patients. This database as well as the specimen tracking and secured data management systems provide an informatics link throughout the participating DF/HCC hospitals which allow for the sharing of clinical outcome data among SPORE investigators. The TAPCD Core also provides state-of-the-art histology and molecular pathology services to SPORE Investigators. These services include: routine histology, histopathological evaluation, immunohistochemistry, in situ hybridization, computer-assisted image analysis, and generation and interrogation of tissue microarrays. In addition, this Core performs tissue microdissection, and DNA and RNA preparation for molecular studies. Finally, the TAPCD Core is responsible for performing mutation and methylation analysis of the VHL gene in clear cell RCC specimens stored in the SPORE tissue bank. Finally, the TAPCD Core collaborates with the Biostatistics Core in data analysis and auditing. This arrangement facilitates the analysis of clinical data from kidney cancer patients consented to our protocols and the correlation of clinical data with results from the various laboratory assays being carried out as part of individual SPORE Projects.

组织采集、病理学和临床数据 (TAPCD) 核心有几个目的，第一个和 最重要的是为各种研究人员维护组织、血液和尿液储存库 参加这个SPORE。这项任务涉及肾癌和肾癌的收集、冷冻和储存。 配对正常肾组织以及来自同意的肾细胞癌患者的血液和尿液。截至 2008 年 7 月， 643 名患者可获得冷冻组织。此外，1088 名患者至少有一份血液样本，741 名患者至少有一份血液样本。 患者至少有一份尿液样本储存在样本库中。 TAPCD 核心还负责维护所有同意肾脏的临床数据库 癌症患者。该数据库以及样本跟踪和安全数据管理系统 在参与的 DF/HCC 医院中提供信息学链接，以便共享 SPORE 研究人员的临床结果数据。 TAPCD 核心还为 SPORE 提供最先进的组织学和分子病理学服务 调查人员。这些服务包括：常规组织学、组织病理学评估、免疫组织化学、 原位杂交、计算机辅助图像分析以及组织的生成和询问 微阵列。此外，该核心还执行组织显微切割以及 DNA 和 RNA 制备 分子研究。最后，TAPCD Core 负责进行突变和甲基化分析 SPORE 组织库中储存的透明细胞 RCC 标本中 VHL 基因的变化。 最后，TAPCD 核心与生物统计核心合作进行数据分析和审计。这 安排有助于分析同意我们协议的肾癌患者的临床数据 以及临床数据与作为一部分进行的各种实验室测定结果的相关性 个人 SPORE 项目。